Loading patent…
AssigneeUniversita Degli Studi Di Genova, Dipartimento Di Medicina Sperimentale
InventorsRoberto Biassoni, Alessandro Moretta, Lorenzo Moretta, Maria Cristina Mingari
Estimating the term…
p75/AIRM1 is expressed on myeloid cells at stages of differentiation and determination of its presence is useful in monitoring cellular proliferation and determining proliferative states of cells, especially myeloid cells in diseases such as chronic myeloid leukemia. Ligands such as antibody molecules, for instance the QA79 monoclonal antibody deposited under accession number ICLC No. PD99003, are useful for methods of diagnosis and treatment, e.g. by way of inhibition of cellular proliferation and induction of apoptosis in cells.
A method of determining the stage of differentiation of myeloid cells, the method comprising contacting myeloid cells in a sample with a ligand directed against p75/AIRM1 receptor, and determining binding of the ligand.
Monoclonal antibody molecule with the antigen-binding site of the QA79 antibody obtainable from the hybridoma deposited as ICLC No. PD99003, or a humanised monoclonal antibody molecule derived from the QA79 antibody and which binds p75/AIRM1, or an isolated human antibody specific for p75/AIRM1 that competes with the QA79 antibody for binding to p75/AIRM1.
A molecular conjugate comprising a ligand directed against p75/AIRM1 and a cytotoxic molecule.
A method of inhibiting proliferation and/or causing apoptosis of myeloid cells, the method comprising contacting the myeloid cells with a ligand directed against p75/AIRM1.
Use of a ligand directed against p75/AIRM1 in the manufacture of a medicament for treatment of a human pathology.
Dependencies are inferred from the claim text.